NETRI
NETRI is a French organ-on-chip company that uses neurons as biological sensors in the world's only 96-well format compartmentalized electrophysiology platform to predict drug safety, neurotoxicity, and sensory effects for pharma, biotech, cosmetics, and academic research customers.
- Company typePrivate
- Founded2018
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NETRI does
NETRI is a French industrial start-up founded in 2018 and headquartered in Lyon, France, that develops microphysiological systems (MPS) and organ-on-chip technologies for the pharmaceutical, biotech, cosmetics, and academic research markets. Its core offering is a standardized compartmentalized electrophysiology platform described as the world's only 96-well format system of its kind, in which living neurons are used as biological sensors — the company's "Neurons-as-a-Sensor" (NaaS) approach — to predict drug-induced neurotoxicity, chemotherapy adverse events, immune responses, and dermatological/cosmetic effects such as itching or irritation. The platform is paired with two proprietary software components, NETRI UpLink® (which extracts Multi-Electrode Array metrics from recordings) and DataLink® (which compiles n-dimensional digital signatures from those metrics), and is benchmarked against a proprietary Digital Signature Library of reference compounds.
NETRI operates a hybrid B2B business model. Commercial revenue is generated through direct enterprise sales of custom organ-on-chip configurations to pharmaceutical, biotech, dermocosmetics, and academic customers, complemented by a self-service e-commerce storefront (shop.netri.com) selling standardized organs-on-chip kits. The company also monetizes consumable wetware/reagents on a usage basis and licenses its software stack, creating a mix of hardware, recurring software, and consumable revenue streams. The company is privately held, employs 11–50 people, and is co-led by CEO Thibault Honegger and CTO/co-founder Florian Larramendy. In February 2025 NETRI raised approximately $5.1 million in funding, and in 2026 it co-founded the Industry Alliance for Microphysiological Systems (IAMPS), the first industry association of its kind in Europe, alongside eight peer MPS providers.
NETRI firmographics
Firmographics- Name
- NETRI
- Legal name
- NETRI
- Website
- https://netri.fr
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NETRI is a French organ-on-chip company that uses neurons as biological sensors in the world's only 96-well format compartmentalized electrophysiology platform to predict drug safety, neurotoxicity, and sensory effects for pharma, biotech, cosmetics, and academic research customers.
- Ownership category
- akta.pro rank
NETRI industry classification
Industry- Product category
- Organ-on-Chip Technology
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)
- akta.pro secondary industry
- Safety Pharmacology (Cardio/CNS/Respiratory) (HLAGAFAB)
Keywords
Where NETRI is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
NETRI business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Organ-on-Chip Hardware and Kits: Sale of organs-on-chip devices and standardized microphysiological system kits including neuro-organs-on-chip devices for research applications.
- Software Platforms: Licensing and sale of proprietary software platforms including NETRI UpLink® and DataLink® for electrophysiological data capture and analysis.
- Wetware/Reagents: Consumable biological materials and reagents for microphysiological system experiments.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
NETRI product offering
Product offeringCore offering
NETRI develops and sells standardized microphysiological systems (organ-on-chip platforms) and proprietary software for preclinical drug safety and efficacy testing. The offering includes the world's only 96-well format compartmentalized electrophysiology platform, organs-on-chip kits, the NETRI UpLink® and DataLink® software platforms for Multi-Electrode Array (MEA) data analysis, and a Digital Signature Library of reference compounds. The technology applies a Neurons-as-a-Sensor (NaaS) approach, using living neurons as biological sensors to predict drug-induced effects including neurotoxicity, chemotherapy adverse events, and dermatological/sensory responses for pharmaceutical, biotech, cosmetics, and academic customers.
Product overview
NETRI offers a unified platform of standardized microphysiological systems and neurons-as-a-sensor (NaaS) technology for preclinical drug testing. The core offering centers on compartmentalized electrophysiology platforms—the world's only 96-well format system—which integrate with proprietary software components NETRI UpLink® (for extracting MEA metrics) and DataLink® (for compiling digital signatures). Results are analyzed against a Digital Signature Library of reference compounds. The product portfolio spans organs-on-chip kits for quick adoption, specialized applications in dermocosmetics, neurotoxicology, oncology, and dermatology testing, and technology components (hardware, wetware, software) available through dedicated pages.
Differentiator
Problem solved
Functional benefit
Products and services
- Standardized Microphysiological Systems (Compartmentalized Electrophysiology Platforms)
- Organs-on-Chip Kits
- Neurons as a Sensor (NaaS)
- NETRI UpLink®
- DataLink®
Quantifiable outcome
- 87% sensitivity in predicting drug-induced liver injury
- +1 more outcomes
Companies that use NETRI
Customer profileSegments4 records
Ideal customer profiles4 records
NETRI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NETRI partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core.
- IAMPS (Industry Alliance for Microphysiological Systems)coreNETRI is a founding member of IAMPS, the world's first industry association dedicated to representing microphysiological systems providers across Europe. The association, operational from Q2 2026, aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization. Founding members include nine companies: Alveolix, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse, headquartered in Switzerland, Italy, the Netherlands, Germany, and France.
- AlveolixcoreSwiss-based founding member of IAMPS (Industry Alliance for Microphysiological Systems), collaborating with NETRI on advancing microphysiological systems industry standards and regulatory acceptance.
- MIMETAScoreNetherlands-based founding member of IAMPS, collaborating with NETRI on microphysiological systems standardization and regulatory data acceptance initiatives.
- InSpherocoreGerman-based founding member of IAMPS, partnering with NETRI on advancing organ-on-chip technology standards and industry collaboration.
- TissUsecoreGerman-based founding member of IAMPS, collaborating with NETRI on microphysiological systems data sharing and device standardization.
- BiomimXcoreItalian-based founding member of IAMPS, partnering with NETRI on MPS industry advancement and regulatory acceptance.
- ChironcoreFounding member of IAMPS, collaborating with NETRI on microphysiological systems industry association initiatives.
- Dynamic42coreGerman-based founding member of IAMPS, partnering with NETRI on microphysiological systems standardization.
- React4LifecoreItalian-based founding member of IAMPS, collaborating with NETRI on advancing microphysiological systems technology and regulatory frameworks.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
NETRI competitors and assessment
Company assessmentDirect peers
- MIMETAS: MIMETAS is a Netherlands-based organ-on-chip company offering the OrganoPlate platform for high-throughput 3D cell-based assays. It is a direct competitor to NETRI in organ-on-chip hardware and reagents, and is a co-founding member of IAMPS alongside NETRI.
- TissUse: TissUse is a German organ-on-chip company developing multi-organ microphysiological systems (Humimic Chip series) for preclinical safety and efficacy testing. It competes directly with NETRI's microphysiological systems and is a co-founding member of IAMPS.
- Emulate: Emulate is a US-based leader in organ-on-chip technology, commercializing the Organ-Chip platform and supporting software for pharma R&D. It competes with NETRI in the same product category and target customer base, with broader organ coverage and greater commercial scale.
- InSphero: InSphero is a Swiss/German company specializing in 3D microtissue and organ-on-chip solutions for drug safety and efficacy testing. It competes directly with NETRI for pharma toxicology budgets and is a co-founding member of IAMPS.
- CN Bio: CN Bio is a UK-based organ-on-chip company offering PhysioMimix single- and multi-organ microphysiological systems for ADME and toxicology applications. It is a direct competitor targeting the same pharma safety-testing use cases as NETRI.
- Alveolix: Alveolix is a Swiss organ-on-chip company focused on lung-on-chip applications for respiratory drug testing. It is a co-founding IAMPS member alongside NETRI and competes in the broader microphysiological systems category.
- BiomimX: BiomimX is an Italian organ-on-chip company developing multi-organ microphysiological platforms for drug discovery. It is a co-founding IAMPS member with NETRI and competes in the same European MPS ecosystem.
- Dynamic42: Dynamic42 is a German organ-on-chip company providing human organ models (liver, gut, lung) for preclinical drug testing and infectious disease research. It is a co-founding IAMPS member alongside NETRI.
- React4Life: React4Life is an Italian company developing microfluidic 3D cell-culture and organ-on-chip platforms for pharma and cosmetics applications. It is a co-founding IAMPS member with NETRI, overlapping in cosmetics and preclinical safety use cases.
Broad incumbents
- Cyprotex (an Evotec company): Cyprotex, owned by Evotec, is a leading CRO providing in vitro ADME and toxicology services including organ-on-chip-based assays. It is comparable to NETRI as a buyer-facing preclinical safety service provider, though operating as a broad incumbent with a much wider service portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NETRI social profiles
Digital presenceNETRI financial estimates
Financial estimateRevenue estimate
Valuation estimate
NETRI leadership team
Management profileNumber of profiles
Profiles2 records
NETRI funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NETRI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NETRI
What does NETRI do?
NETRI develops and sells standardized microphysiological systems (organ-on-chip platforms) and proprietary software for preclinical drug safety and efficacy testing. The offering includes the world's only 96-well format compartmentalized electrophysiology platform, organs-on-chip kits, the NETRI UpLink® and DataLink® software platforms for Multi-Electrode Array (MEA) data analysis, and a Digital Signature Library of reference compounds. The technology applies a Neurons-as-a-Sensor (NaaS) approach, using living neurons as biological sensors to predict drug-induced effects including neurotoxicity, chemotherapy adverse events, and dermatological/sensory responses for pharmaceutical, biotech, cosmetics, and academic customers.
Is NETRI a public or private company?
NETRI is a private company. It is classified as unknown and is currently operating.
When was NETRI founded?
NETRI was founded in 2018. It employs 11 to 50 people.
Where is NETRI based?
NETRI is headquartered in Lyon, France, in the Europe region.
How does NETRI make money?
Three revenue lines are on record. Organ-on-Chip Hardware and Kits are the primary driver. The others are software Platforms and wetware/Reagents.
Who are NETRI's main competitors?
Direct peers on record are MIMETAS, TissUse, Emulate, InSphero, CN Bio, Alveolix, BiomimX, Dynamic42 and React4Life. Cyprotex (an Evotec company) is listed as a broad incumbent.
Does NETRI have an API?
No public API is recorded for NETRI.
What industry is NETRI in?
NETRI's product category is Organ-on-Chip Technology. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAGAFAB, Safety Pharmacology (Cardio/CNS/Respiratory). Its NAICS code is 334516 and its SIC code is 3826.